About: Exenatide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exenatide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B6276-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B6277-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B6278-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B6279-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16230722 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	Mean terminal half-life is 2.4 hours. (en)
http://linked.open...ugbank/indication	Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control. (en)
sameAs	Exenatide
Title	Exenatide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/drugbank/DB01276 http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/kegg-drug/D04121 http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/national-drug-code-directory/66780-210-07 http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/pharmgkb/PA164749238 http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/wikipedia/Exenatide
http://linked.open...mechanismOfAction	Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals. (en)
http://linked.open...drugbank/packager	Medisca Inc. Baxter International Inc. Akorn strides llc Apotex inc richmond hill Apothecon inc div bristol myers squibb
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5424286 http://linked.opendata.cz/resource/drugbank/patent/6872700
http://linked.open...outeOfElimination	Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. (en)
http://linked.open.../drugbank/synonym	Exenatide (en) Byetta (en) AC2993 (en) Synthetic exendin-4 (en) AC 2993 (en) AC-2993 (en) AC002993 (en) AC2993a (en) Bydureon (en) Exenatide synthetic (en)
http://linked.open...drugbank/toxicity	Effects of the overdoses included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations. (en)
http://linked.open...umeOfDistribution	* 28.3 L (en)
http://linked.open...ynthesisReference	Matthieu Giraud, Anne-Sophie Droz, Stephane Varray, El Djouhar Rekai, Marie-Helene Brichard, Daniel Latassa, Christine Devijver, Pascal Gilles, Jeanne-Marie Cauvin, Fernando Albericio, Marta Paradis Bas, "PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE." U.S. Patent US20110046349, issued February 24, 2011. (en)
foaf:page	http://www.drugs.com/cdi/exenatide.html http://www.rxlist.com/cgi/generic/byetta.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B627B-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B627A-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Exenatide
http://linked.open...ugbank/absorption	Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	141758-74-9 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* Apparent cl=9.1 L/hr (en)
http://linked.open...gbank/containedIn	Byetta 5 MCG Pen 5 mcg/0.02ml Solution 1.2ml Pen Byetta 5 mcg dose pen inj Byetta 10 MCG Pen 10 mcg/0.04ml Solution 2.4ml Pen

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 121 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software